Navigation Links
Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Date:7/14/2008

d be delisted from The NASDAQ Capital Market and other risks and challenges detailed in the Company's filings with the U.S. Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

Brian Ritchie - FD

212-850-5683

brian.ritchie@fd.com

Matt Duch - FD

212-850-5758

matthew.duch@fd.com

Corporate Communications Contact:

John Procter - Gibraltar Associates

202-879-5808

jprocter@gibraltar-llc.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... WA , Sept. 17, 2014 /PRNewswire/ - Oncothyreon ... it intends to offer and sell shares of its ... separate but concurrent underwritten public offerings.  The Series A ... of Oncothyreon Common Stock, provided that conversion will be ... affiliates would beneficially own more than 4.99% of the ...
(Date:9/17/2014)... A biodegradable polymer can be ... bacteria, fungi, and algae into smaller units (monomers) ... compounds, carbon dioxide, and humus in a specified ... improved costs, biodegradable polymers are proving to be ... conventional polymers. Primary factors that are responsible for ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... , Sept. 17, 2014 RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced that it has been granted ... Trademark Office on its unique delivery system for ... to phagocytic cells for the treatment of diseases ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... CHICAGO, Sept. 28, 2011 GTL Resources PLC (AIM: GTL) ... on the state of its business. Julia Henderson, the non-executive ... trends and reaffirmed the current business approach: ... with expectations and in the six month period ending September ...
... Managing RA: The Strong Woman,s Approach ... women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org. ... are two to three times more likely to develop the ... provides practical solutions and exercise advice specifically designed to ...
... delivery systems, solar cells, industrial catalysts and video displays ... possess two chemically distinct sides. These particles are named ... chemical faces allow them to form novel structures and ... of Janus particles down to a few nanometers in ...
Cached Biology Technology:The Strong Woman's Approach to Managing Rheumatoid Arthritis 2The Strong Woman's Approach to Managing Rheumatoid Arthritis 3The Strong Woman's Approach to Managing Rheumatoid Arthritis 4New technique maps twin faces of smallest Janus nanoparticles 2
(Date:9/17/2014)... from the Copenhagen Centre for Social Evolution and Yale ... that birth weight and -length can partially predict the ... as autism and schizophrenia later in life. The study ... subsequent hospital diagnoses for up to 30 years, and ... study is published today in the Proceedings of ...
(Date:9/17/2014)... 2014 Researchers at UTSouthwestern Medical Center have found ... apolipoprotein E, called apoE3, helps repair the lining of ... not get the benefit of this repair, putting them ... that we have identified one mechanism by which apoE3 ... variant, apoE4, is detrimental," said Dr. Philip Shaul ...
(Date:9/17/2014)... a great deal about complex social behavior by studying ... to teach too. , With their unusually large brains ... live in a complex social environment---not merely in a ... ants, but in a dynamic setting of alliances and ... mammals: dolphins, whales, primates, and social carnivores, like hyenas ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Protein variant may boost cardiovascular risk by hindering blood vessel repair 2Being social: Learning from the behavior of birds 2
... over recent years have established a foothold in understanding ... it might contribute to aging and lifespan are not ... p53 function in fruit flies show new evidence that ... against tumor formation, normal levels of p53 activity--at least ...
... be published in the January 2006 issue of Nature ... Memorial Sloan-Kettering Cancer Center have devised a novel strategy ... to genetically reverse sickle cell disease (SCD) in human ... way to genetically correct this debilitating blood disease using ...
... years, biologists have searched for evolutionary clues to this ... play in the evolution of the postreproductive lifespan? ... years, postreproductive females should contribute to the fitness of ... effect." Though many mammals, including lions and baboons, rear ...
Cached Biology News:New clues to the dark side of a key anti-tumor guardian 2Sickle cell disease corrected in human models using stem cell-based gene therapy 2Getting an evolutionary handle on life after reproduction 2
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
Biology Products: